{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:08:08Z","timestamp":1781629688882,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","award":["2018-00706\/ESR-16-12287"],"award-info":[{"award-number":["2018-00706\/ESR-16-12287"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","award":["2018-00603"],"award-info":[{"award-number":["2018-00603"]}],"id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","award":["PHRC-K_2016-078"],"award-info":[{"award-number":["PHRC-K_2016-078"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.breast.2025.104549","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:17:17Z","timestamp":1754435837000},"page":"104549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study"],"prefix":"10.1016","volume":"83","author":[{"given":"T.","family":"De La Motte Rouge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-S.","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Borcoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Augereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Charafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dass\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.breast.2025.104549_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.breast.2025.104549_bib2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104549_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102142","article-title":"Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future","volume":"93","author":"Rey-Cardenas","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.breast.2025.104549_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1470-2045(22)00509-5","article-title":"Adjuvant immunotherapy for renal cell carcinoma","volume":"23","author":"Sendur","year":"2022","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.breast.2025.104549_bib5","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104549_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2025.104549_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.breast.2025.104549_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106482","article-title":"RAMPART: a phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse","volume":"108","author":"Oza","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"11","key":"10.1016\/j.breast.2025.104549_bib9","article-title":"Pembrolizumab plus chemotherapy in lung cancer","volume":"379","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.breast.2025.104549_bib10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104549_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.cllc.2016.03.003","article-title":"A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study","volume":"17","author":"Planchard","year":"2016","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.breast.2025.104549_bib12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.breast.2025.104549_bib13","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1245\/s10434-018-6620-5","article-title":"Immunotherapy for breast cancer is finally at the doorstep: immunotherapy in breast cancer","volume":"25","author":"De La Cruz","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.breast.2025.104549_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000255","article-title":"Targeting immune checkpoints in breast cancer: an update of early results","volume":"2","author":"Solinas","year":"2017","journal-title":"ESMO Open"},{"issue":"21","key":"10.1016\/j.breast.2025.104549_bib15","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104549_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2025.104549_bib17","first-page":"275","article-title":"Corrigendum: \"combinatorial Strategies for the Induction of Immunogenic Cell Death\"","volume":"6","author":"Bezu","year":"2015","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.breast.2025.104549_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2025.104549_bib19","first-page":"3025","article-title":"Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy","volume":"7","author":"Demaria","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.breast.2025.104549_bib20","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2021.10.002","article-title":"Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: iMpassion130 final overall survival analysis': annals of oncology 2021; 32: 983-993","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104549_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001112","article-title":"Atezolizumab in metastatic triple-negative breast cancer: iMpassion130 and 131 trials - how to explain different results?","volume":"5","author":"Franzoi","year":"2020","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.breast.2025.104549_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.breast.2025.104549_bib23","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2025.104549_bib24","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.breast.2025.104549_bib25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1159\/000526481","article-title":"Current research status of metronomic chemotherapy in combination treatment of breast cancer","volume":"45","author":"Liu","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2025.104549_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.breast.2025.104549_bib27","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Investig"},{"issue":"7","key":"10.1016\/j.breast.2025.104549_bib28","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2025.104549_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andre","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104549_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104549_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.breast.2025.104549_bib32","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.5301\/tj.5000543","article-title":"Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study","volume":"103","author":"Cazzaniga","year":"2017","journal-title":"Tumori"},{"key":"10.1016\/j.breast.2025.104549_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/769790","article-title":"Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study","volume":"2014","author":"Cazzaniga","year":"2014","journal-title":"Int J Breast Cancer"},{"issue":"6","key":"10.1016\/j.breast.2025.104549_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100646","article-title":"MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors","volume":"7","author":"Vicier","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.breast.2025.104549_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24670","article-title":"Metronomic chemotherapy and drug repurposing: a paradigm shift in oncology","volume":"10","author":"Jan","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.breast.2025.104549_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12282-022-01426-1","article-title":"CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients","volume":"30","author":"Bailleux","year":"2023","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.breast.2025.104549_bib37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104549_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-Low\/Negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.104549_bib39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with >\/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur J Cancer"},{"issue":"27","key":"10.1016\/j.breast.2025.104549_bib40","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104549_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104549_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104549_bib43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","article-title":"Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial","volume":"27","author":"Bachelot","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104549_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2025.104549_bib45","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2025.104549_bib46","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-GS2-10","article-title":"Abstract GS2-10: Nimbus: a phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)","volume":"82","author":"Barroso-Sousa","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2025.104549_bib47","first-page":"311","article-title":"Pembrolizumab in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide: a clinical and translational prospective study","volume":"15","author":"Mery","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"16","key":"10.1016\/j.breast.2025.104549_bib48","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.18632\/oncotarget.2289","article-title":"HDAC inhibitors and immunotherapy; a double edged sword?","volume":"5","author":"Kroesen","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.breast.2025.104549_bib49","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos","year":"2024","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.breast.2025.104549_bib50","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104549_bib51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104549_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:00:35Z","timestamp":1772877635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"alternative-id":["S0960977625005661"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104549","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104549"}}